Purposes: To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. Scope: Only biopsied men (sextant) were included. A total of 1011 biopsy sessions were carried out in 770 men; 172 underwent a second prostate biopsy and 51 a third biopsy. During the first biopsy round, 111 cancers were found (14.4%), 27 in the second (15.7%), and five during the third round (9.8%), P ¼ 0.156. Only high-grade PIN or atypia were identified as independent predictors or PCa detection in subsequent biopsies (P ¼ 0.008). A nonsignificant increase of clinically localized tumors, and a decrease of metastatic and poorly differentiated cases were found when more biopsy sessions were needed for detection. Conclusions: A nonsignificant trend to lower cancer detection rates and less clinical relevance of the tumors detected can be observed when more biopsy rounds are needed for detection.
Introduction
The potential survival benefit of prostate cancer (PCa) screening is controversial at the present moment, and conclusions from large ongoing randomized studies are still awaited. 1 Until such results are produced, the impact of screening on some other factors (PCa detection rate, clinical features of the detected cancers) has been often considered.
Unfortunately, the diagnostic yield of prostate biopsy depends strongly on the biopsy technique used, 2, 3 and the highest cancer detection is usually achieved by more extensive biopsy protocols. 4 Given the intrinsic limitations of prostate biopsy in terms of cancer detection, biopsies are sometimes repeated after a time interval depending on each center's protocol (usually after a new screening attendance), or even 'immediately' when risk cases are considered. Common risk conditions are high-grade prostatic intraepithelial neoplasia (HG-PIN) and atypia because they may coexist with nondetected cancers and are also considered as premalignant lesions. 5, 6 In such cases, a repeat biopsy can be performed early (6 weeks later) with no extra morbidity. 7 Attempts have been made in order to identify the cases most likely to harbor PCa on repeat prostate biopsy. [8] [9] [10] [11] Potential predictive variables as serum total and free prostate-specific antigen (PSA) level, digital rectal examination (DRE) or transrectal ultrasound (TRUS) findings, PSA density, PSA velocity, the presence of HG-PIN or atypia, etc have been studied in order to identify the optimal candidates for repeat biopsy.
In the present study, we have attempted to address cancer detection in men with respect to the number of biopsy sessions performed. We also tried to identify which factors accounted for a higher risk of subsequent cancer detection after a negative biopsy. Also, we analyzed the clinical characteristics of the tumors with regard to the number of biopsy sessions needed for detection.
Methods
Our study was started from a database including the records of 5200 men, who attended a PSA-based (Beckmann-Access TM) PCa screening program at our Centre. A total of 2784 of those men were recruited during the years 1993-1995, and 2416 were recruited from year 1996 to 1999 and included in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). The final population included in the study comprised 770 men with at least one prostate biopsy session performed.
All prostate biopsies were TRUS-guided and sextant, regardless of the number of previous biopsy sessions. Indication for the biopsy was fixed according to the ongoing protocol at each period of the screening program. First protocol (indication for biopsy when PSA 410 ng/ml, when abnormal DRE, or when PSA density 40.15 ng/ml/cm 3 in the range of PSA 4-10 ng/ ml) was applied from January 1993 to December 1995. Second protocol (biopsy when PSA 44 ng/ml) was used from January 1996 to April 1998. Third protocol (biopsy when PSA X3 ng/ml) from May 1998 to December 2001. Fourth protocol (same indication for biopsy as third protocol, but also including men with PSA 1-2.99 ng/ml when free to total PSA ratio p20%) from January 2002 to December 2002.
We recorded the biopsy results obtained in all biopsy rounds. Repeat biopsies were performed 'immediately' (usually 1-2 months later) only when HG-PIN or atypia were found in a previous biopsy session, or after a longer period (usually 1-2 y later) in the context of a new rescreen visit (new attendance with tests performed again) in the rest of the cases.
Time interval between biopsy rounds was also recorded. Cancer detection rates were calculated with regard to the number of biopsy sessions performed and with respect to some factors as age, the existence of family history of PCa, DRE and TRUS findings, PSA range, PSA density, PSA velocity, and the presence or HG-PIN or atypia in the previous biopsy round. Univariate differences among detection rates with regard to the mentioned factors and the number of biopsy sessions carried out were analyzed with w 2 -test. The role of the factors mentioned above as independent predictors of a positive subsequent biopsy was assessed by means of multivariate Cox regression analysis.
The clinical features of the cancers detected (clinical stage, Gleason score, PSA level and other PSA-derived indexes) were analyzed taking into account the number of biopsy sessions needed for diagnosis. Differences were analyzed with the aid of w 2 -test for categorical variables and nonparametric Kruskal-Wallis test for numeric variables (PSA derivatives).
Statistical processing was carried out with the aid of a PC computer with Microsoft Access (Microsoft Corp., Chicago, IL, USA) and the statistical package SPSS (SPSS Inc, Chicago, IL, USA). Significance level was reached when Po0.05.
Results
A total of 770 men who underwent at least one biopsy session were finally included in the study. A total of 1011 biopsy sessions were carried out in those men (mean 1.31 biopsies per man): 172 underwent a second prostate biopsy, 51 a third biopsy, 16 a fourth biopsy and two men with a fifth biopsy session. A total of 298 biopsies were performed following the first protocol ongoing at our Centre, 148 according to the second protocol, 266 to the third protocol, and 299 to the fourth protocol.
In Table 1 , the demographic characteristics of the studied population are shown. Mean time intervals between biopsy sessions (Table 2) were 539 days (first to second biopsy) and 533 (second to third biopsy).
During the first biopsy round, a total of 770 biopsies were performed and 111 cancers found (Table 3 , detection rate 14.4%). Among the 172 men with previous negative biopsy who underwent a second biopsy, 27 cancers were detected (15.7%). Five cancers were found in the group of 51 men with a third biopsy session (9.8%). No statistical differences in cancer detection were found with regard to the number of biopsy sessions performed (P ¼ 0.156).
In univariate analysis, cancer detection was higher in the cases with abnormal DRE but only in the first biopsy session (P ¼ 0.008), with an important decline of DREpositive men in subsequent rounds. The presence of HG-PIN or atypia in the first biopsy session was associated with higher detection rates in subsequent rounds (Po0.001). No differences in terms of cancer detection were noted with regard to other variables as age, family After Cox regression analysis, only the history of HG-PIN or atypia in a previous biopsy round was identified as an independent predictor of PCa detection in subsequent biopsies (P ¼ 0.008).
In Table 4 , the characteristics of the cancers detected with regard to the number of biopsy sessions needed and other variables are shown. A nonsignificant increase of clinically (P ¼ 0.357) and pathologically (P ¼ 0.108) localized tumors and a decrease of metastatic cases were found as the number of biopsies needed for detection was higher. Also, a decrease of cases with Gleason score 8-10 was noted as more biopsy rounds were carried out (not significant, P ¼ 0.707).
Discussion
In the present study, we attempted to address changes in cancer detection rates with regard to the number of Prostate cancer detection and multiple biopsy sessions M Lujan et al biopsy sessions performed, to identify independent predictors for a positive subsequent biopsy, and to analyze tumor characteristics with regard to the number of biopsy rounds needed for detection.
We found similar detection rates in men at first and second biopsy session (14.4 and 15.7%, respectively), in a similar range as reported in the revised literature.
11
Those detection rates decreased during the third biopsy round (9.8%), although such reduction did not reach statistical significance in our study. Results in the same direction were reported by Djavan et al 12 in a prospective study of 1051 biopsied men where cancer detection rates on biopsy rounds 1, 2, 3, and 4 were 22, 10, 5, and 4%, respectively. Nevertheless, the observed reduction of PCa detection rate after the third-biopsy session in our study was not as marked as in the observed literature. A possible explanation could be the continuous usage in our protocols of sextant biopsies regardless of the number of previous biopsy sessions performed. In other words, it might be possible that if we used more extensive protocols in the first-and second-biopsy rounds, a greater decline of detection rate could be expected at the third biopsy.
Our study could be criticized because of the usage of sextant biopsies. We are aware that the current knowledge among urologists advocates the use of more extensive sets of biopsies in order to increase cancer detection rates. Again, we should consider that the prostate often harbors latent cancer, and there is no surprise that taking more cores increases the probability of detection of such tumors. Unfortunately, there is no current evidence of the effect of biopsy protocol on prostate cancer mortality. 13 Only the presence of HG-PIN or atypia was found as an independent predictor of further cancer detection at repeat biopsies. Similar results can be found in the revised literature. 10, 11 Notwithstanding the relatively low PCa detection rate after the diagnosis of HG-PIN (16.7 and 17.6% in the second-and third-biopsy sessions, respectively) found in our setting, some studies have pointed out that cancer detection after PIN is not as high as traditionally expected, with rates not very different from men with a prior benign (normal) biopsy result.
14 Similar findings were observed in our study, with a cancer detection after an HG-PIN result that almost equals the detection rate of men submitted for a second-biopsy session because of an elevated PSA. Nevertheless, when a third-biopsy round was performed in our study, the previous detection of HG-PIN or atypia really made the difference in terms of cancer detection.
A nonsignificant trend to more localized and less metastatic tumors was found when more biopsy sessions were needed for detection. Similar results were reported in the mentioned study by Djavan et al, 12 with clinically localized disease in 64, 67, 91, and 100% of the cancers detected on the first-, second-, third-, and fourth-biopsy round, respectively. In our study, cancers were clinically localized in 78, 92, and 100% of the cases on first-, second-, and third-biopsy round, respectively. We did not detect any metastatic cases at the second-and thirdbiopsy sessions. With respect to the Gleason score, a marked but nonsignificant decrease of Gleason score of 7 or higher was noted in our study on the second and third biopsy rounds. This decrease was significant in the study mentioned above 12 in men who underwent a third biopsy session. Although the amount of biopsied men was not large enough to address significant differences in our study, a clear trend to more localized and more differentiated cancers was observed at repeat biopsy after a prior negative result.
The clinical relevance of the tumors detected can be estimated with the aid of the studied variables, as PSA levels at diagnosis, clinical stage, or Gleason score. A nonsignificant increase of more localized tumors, and less metastatic and poorly differentiated cancers was observed when more biopsy rounds were needed for detection. Nevertheless, overdetection (detection of tumors with little impact on patient survival) is a major drawback to keep in mind when screening for PCa. The real impact of repeat screening on overall and cancerspecific survival in will only be answered after completion of ongoing randomized trials. 1 
Conclusions
Cancer detection rates showed a nonsignificant decline in men who underwent a third biopsy session. Only the presence of high-grade PIN or atypia was identified as an independent predictor of cancer in repeat biopsies. A nonsignificant trend toward more localized and differentiated tumors was observed in the cases with more biopsy rounds needed for detection.
